• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Pathogen Reduced Platelets are Non-Inferior to Conventional Platelets for Hematology Patients

October 28, 2021

Results for the PIPER Phase 4 study of psoralen-UVA pathogen reduced platelets (PRPC) (Cerus Corporation) following transfusion were recently presented at the 2021 Annual AABB meeting.   In this prospective, open-label, two-arm study at 15 U.S. hospitals, 1068 hematology-oncology platelet-dependent patients (mean age, 57.0 years) received PRPC, and 1223 comparable patients (mean age, 50.6 years) received conventional platelet concentrates (CPC).  Patients who received PRPC were less likely to have severe pulmonary injury; 2.9% of patients who received PRPC required mechanical ventilation compared to 4.6% of patients who received CPC (p=0.039).  Furthermore, other clinically significant adverse events were comparable in both study arms.  RBC utilization was similar, and no differences in safety were observed.  However, data on increases in platelet count increment were not assessed.  Preliminary results from the PIPER study suggest that PRPC are safe for routine clinical use in hematology-oncology patients.

Reference:

Snyder EL, Wheeler A, Refaai MA, Cohn CS, et al.  The PIPER Phase 4 Study:  Pathogen inactivated platelets entering routine practice.  2021 Virtual AABB Annual Meeting, October 17-19, 2021. Transfusion 2021

Filed Under

  • News
  • Platelet Transfusion

Recommended

  • Fresh Red Blood Cells May Be Associated with Mortality Depending on How They Are Processed Before Transfusion

  • Twelve Month Donor Deferral for MSM May Not Increase Risk of Transfusion-Transmitted HIV

  • Ehrlichia Ewingii May be Transmitted Through Transfusion

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Plasma Equivalent to Clotting Factor Concentrates for Initial Resuscitation of Patients with Severe Trauma

  • Personalized Prediction Model of Prophylactic Platelet Transfusions for Preterm Infants

  • Caffeine in Donor Blood Reduces Quality of Stored RBCs

  • Ferritin Levels Needed to Assess Hemoglobin Recovery after Blood Donation

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley